The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

On the evening of April 25, BGI Genomics released its first quarterly financial results for 2023.

As expected, significantly lower demand for COVID-19 tests leads to a decrease in Group sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%.

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the first quarter ended April 1, 2023.

Recently, the General Office of the State Council communicated Measures of Ministry of Commerce and the Ministry of Science and technology (MOST) for Further Encouraging Foreign Investment in Establishing Research and Development (R&D) Centers in China.

Labcorp, a leading global life sciences company, today announced results for the first quarter ended March 31, 2023, and updated full-year guidance.

Qiagen said Monday that its QIAstat-Dx syndromic testing system is expected to be available soon in Japan with a SARS-CoV-2 Respiratory Panel that can detect more than 20 pathogens from a patient sample.

Blood gas diagnosis mainly involves measuring the pH value, pCO2, pO2, and other gases dissolved in human blood to understand the body's respiratory function and acid-base balance status.

China's foreign ministry said on Tuesday that all inbound travellers will only need to show COVID-19 antigen tests result taken within 48 hours before boarding flights starting April 29, dropping the PCR test requirement.

Curative Inc., a leading health services company that recently launched a new health plan out of Texas, announces the spin-off of Sensible Diagnostics, whose aim is to commercialize their groundbreaking point-of-care PCR testing platform.

Stockholm, Sweden-based Devyser Diagnostics on Monday announced that it has inked a collaboration and distribution agreement that gives Thermo Fisher Scientific the exclusive rights to commercialize its post-transplant portfolio of next-generation sequencing (NGS) products in North America and Europe.